Abstract
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVATM in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVATM in Subjects With Severe Hypertriglyceridemia (EVOLVE II)